home / stock / cvac / cvac articles
Canadian Biotech company Acuitas Therapeutics and Germany-based CureVac NV (NASDAQ:CVAC) have settled Acuitas’ lawsuit ov...
CureVac N.V. (NASDAQ:CVAC) released interim data on Thursday, April 4, from studies it conducted on its seasonal influenza vaccine candidate. The ...
CureVac N.V. (NASDAQ: CVAC) shares are trading higher on Friday. The company announced interim data from the ongoing Phase 2 study assessing m...
A German court has invalidated a patent central to CureVac N.V's (NASDAQ: CVAC) lawsuit against BioNTech SE (NASDAQ: BNTX) ...
U.S. stocks traded higher, with the Dow Jones index gaining around 150 points on Tuesday. Shares of bluebird bio, Inc. (NASDAQ: BLUE) shares fell ...
Biotech company Acuitas Therapeutics has filed a lawsuit in Virginia federal court against Germany-based CureVac SE (NASDAQ: CV...
Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing...
News, Short Squeeze, Breakout and More Instantly...
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone pa...
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization Prioritization of high-value opportunities in oncology and other selected diseases, leveraging proprietary mRNA tec...
Phase 2 study to assess updated formulations for improved immune responses of multivalent vaccine candidate against influenza B strain Study initiated following previously reported interim data from Phase 2 Part of combined Phase 1/2 study in seasonal influenza Composition of vaccine ca...